Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy.

Autor: Repellin M; Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy; University of Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 bd 11 Novembre 1918, 69622 Villeurbanne, France., Carton F; Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy., Boschi F; Department of Computer Science, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy., Galiè M; Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy., Perduca M; Department of Biotechnology, Biocrystallography and Nanostructure Laboratory, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy., Calderan L; Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy., Jacquier A; Institut NeuroMyogène, University of Lyon1, CNRS UMR 5310, INSERM U1217, 8 avenue Rockefeller, 69008 Lyon, France; Centre de Biotechnologie Cellulaire, CBC Biotec, CHU de Lyon - Hospices civils de Lyon groupement Est, Bron, France., Carras J; Institut NeuroMyogène, University of Lyon1, CNRS UMR 5310, INSERM U1217, 8 avenue Rockefeller, 69008 Lyon, France; Centre de Biotechnologie Cellulaire, CBC Biotec, CHU de Lyon - Hospices civils de Lyon groupement Est, Bron, France., Schaeffer L; Institut NeuroMyogène, University of Lyon1, CNRS UMR 5310, INSERM U1217, 8 avenue Rockefeller, 69008 Lyon, France; Centre de Biotechnologie Cellulaire, CBC Biotec, CHU de Lyon - Hospices civils de Lyon groupement Est, Bron, France., Briançon S; University of Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 bd 11 Novembre 1918, 69622 Villeurbanne, France., Lollo G; University of Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 bd 11 Novembre 1918, 69622 Villeurbanne, France., Malatesta M; Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy. Electronic address: manuela.malatesta@univr.it.
Jazyk: angličtina
Zdroj: Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2023 Jan; Vol. 47, pp. 102623. Date of Electronic Publication: 2022 Oct 26.
DOI: 10.1016/j.nano.2022.102623
Abstrakt: In a context of drug repurposing, pentamidine (PTM), an FDA-approved antiparasitic drug, has been proposed to reverse the splicing defects associated in myotonic dystrophy type 1 (DM1). However, clinical use of PTM is hinder by substantial toxicity, leading to find alternative delivery strategies. In this work we proposed hyaluronic acid-based nanoparticles as a novel encapsulation strategy to efficiently deliver PTM to skeletal muscles cells. In vitro studies on C2C12 myoblasts and myotubes showed an efficient nanoparticles' internalization with minimal toxicity. More interestingly, our findings evidenced for the first time the endosomal escape of hyaluronic acid-based nanocarriers. Ex vivo studies showed an efficient nanoparticles' internalization within skeletal muscle fibers. Finally, the therapeutic efficacy of PTM-loaded nanosystems to reduce the number of nuclear foci has been demonstrated in a novel DM1 in vitro model. So far, current data demonstrated the potency of hyaluronic acid-based nanosystems as efficient nanocarrier for delivering PTM into skeletal muscle and mitigate DM1 pathology.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: